Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
Abbvie, Absent, assay, attained, backlog, Bio, cited, clarity, CRL, deepening, defray, disposition, Division, evergreen, experimental, Galderma, graphical, IPR, Judgement, legacy, LP, Nestl, opponent, OPUL, OPULTM, Owner, Panel, parent, Pharma, postmarketing, preservation, preserve, prudent, rebrand, Rehearing, reinspection, rescind, resistance, resubmission, Skin, SNC, Substitute, substrate, TherapeuticsTM, tie, variant, waive
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view